Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
The administration of a third dose of a vaccine against SARS-CoV-2 has increased protection against disease transmission and severity. However, the kinetics of neutralizing antibodies against the virus has been poorly studied in cancer patients under targeted therapies. Baseline characteristics and...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/9/1474 |
| _version_ | 1797481556166574080 |
|---|---|
| author | Flora Zagouri Alkistis Papatheodoridi Michalis Liontos Alexandros Briasoulis Aimilia D. Sklirou Efthymia Skafida Oraianthi Fiste Christos Markellos Angeliki Andrikopoulou Konstantinos Koutsoukos Maria Kaparelou Eirini Gkogkou Ioannis P. Trougakos Meletios-Athanasios Dimopoulos Evangelos Terpos |
| author_facet | Flora Zagouri Alkistis Papatheodoridi Michalis Liontos Alexandros Briasoulis Aimilia D. Sklirou Efthymia Skafida Oraianthi Fiste Christos Markellos Angeliki Andrikopoulou Konstantinos Koutsoukos Maria Kaparelou Eirini Gkogkou Ioannis P. Trougakos Meletios-Athanasios Dimopoulos Evangelos Terpos |
| author_sort | Flora Zagouri |
| collection | DOAJ |
| description | The administration of a third dose of a vaccine against SARS-CoV-2 has increased protection against disease transmission and severity. However, the kinetics of neutralizing antibodies against the virus has been poorly studied in cancer patients under targeted therapies. Baseline characteristics and levels of neutralizing antibodies at specific timepoints after vaccination were compared between patients suffering from breast, ovarian or prostate cancer and healthy individuals. Breast cancer patients were treated with cyclin D kinase 4/6 inhibitors and hormonal therapy, ovarian cancer patients were treated with poly (ADP-ribose) polymerase inhibitors and prostate cancer patients were treated with an androgen receptor targeted agent. Levels of neutralizing antibodies were significantly lower in cancer patients compared to healthy individuals at all timepoints. Antibodies’ titers declined over time in both groups but remained above protective levels (>50%) at 6 months after the administration of the second dose. The administration of a third dose increased neutralizing antibodies’ levels in both groups. The titers of protective against SARS-CoV-2 antibodies wane over time and increase after a third dose in cancer patients under treatment. |
| first_indexed | 2024-03-09T22:16:18Z |
| format | Article |
| id | doaj.art-74d451f98c544aa9a0a17db5f960c0f7 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:16:18Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-74d451f98c544aa9a0a17db5f960c0f72023-11-23T19:21:43ZengMDPI AGVaccines2076-393X2022-09-01109147410.3390/vaccines10091474Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted AgentsFlora Zagouri0Alkistis Papatheodoridi1Michalis Liontos2Alexandros Briasoulis3Aimilia D. Sklirou4Efthymia Skafida5Oraianthi Fiste6Christos Markellos7Angeliki Andrikopoulou8Konstantinos Koutsoukos9Maria Kaparelou10Eirini Gkogkou11Ioannis P. Trougakos12Meletios-Athanasios Dimopoulos13Evangelos Terpos14Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceSection of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceSection of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, GreeceSection of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 11528 Athens, GreeceThe administration of a third dose of a vaccine against SARS-CoV-2 has increased protection against disease transmission and severity. However, the kinetics of neutralizing antibodies against the virus has been poorly studied in cancer patients under targeted therapies. Baseline characteristics and levels of neutralizing antibodies at specific timepoints after vaccination were compared between patients suffering from breast, ovarian or prostate cancer and healthy individuals. Breast cancer patients were treated with cyclin D kinase 4/6 inhibitors and hormonal therapy, ovarian cancer patients were treated with poly (ADP-ribose) polymerase inhibitors and prostate cancer patients were treated with an androgen receptor targeted agent. Levels of neutralizing antibodies were significantly lower in cancer patients compared to healthy individuals at all timepoints. Antibodies’ titers declined over time in both groups but remained above protective levels (>50%) at 6 months after the administration of the second dose. The administration of a third dose increased neutralizing antibodies’ levels in both groups. The titers of protective against SARS-CoV-2 antibodies wane over time and increase after a third dose in cancer patients under treatment.https://www.mdpi.com/2076-393X/10/9/1474SARS-CoV-2vaccinationcancerARTACDK4/6 inhibitorsPARP inhibitors |
| spellingShingle | Flora Zagouri Alkistis Papatheodoridi Michalis Liontos Alexandros Briasoulis Aimilia D. Sklirou Efthymia Skafida Oraianthi Fiste Christos Markellos Angeliki Andrikopoulou Konstantinos Koutsoukos Maria Kaparelou Eirini Gkogkou Ioannis P. Trougakos Meletios-Athanasios Dimopoulos Evangelos Terpos Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents Vaccines SARS-CoV-2 vaccination cancer ARTA CDK4/6 inhibitors PARP inhibitors |
| title | Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents |
| title_full | Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents |
| title_fullStr | Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents |
| title_full_unstemmed | Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents |
| title_short | Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents |
| title_sort | assessment of postvaccination neutralizing antibodies response against sars cov 2 in cancer patients under treatment with targeted agents |
| topic | SARS-CoV-2 vaccination cancer ARTA CDK4/6 inhibitors PARP inhibitors |
| url | https://www.mdpi.com/2076-393X/10/9/1474 |
| work_keys_str_mv | AT florazagouri assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT alkistispapatheodoridi assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT michalisliontos assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT alexandrosbriasoulis assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT aimiliadsklirou assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT efthymiaskafida assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT oraianthifiste assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT christosmarkellos assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT angelikiandrikopoulou assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT konstantinoskoutsoukos assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT mariakaparelou assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT eirinigkogkou assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT ioannisptrougakos assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT meletiosathanasiosdimopoulos assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents AT evangelosterpos assessmentofpostvaccinationneutralizingantibodiesresponseagainstsarscov2incancerpatientsundertreatmentwithtargetedagents |